Tot Bio stages IPO in HK, takes home USD 63m

China-based Tot Biopharmaceutical International Co., Ltd (1875.HK) has made an initial public offering (IPO) of 9 million shares to the Stock Exchange of Hong Kong (HKEX) priced at HKD 6.55 (USD 0.84) per share. That meant a take-home of HKD 511 million (USD 63.3 million) net. Center Laboratories Inc., Vivo Capital, and Nien Hsing BVI made cornerstone investments of 23,928,400 shares, equating to 26.59% of the global issuance.

Tot Bio is a wholly owned subsidiary of Taiwan-based TTY Biopharm set up in Suzhou in 2010. The firm is dedicated to anti-cancer drug research and development, manufacturing and marketing.

Tot Bio has 7 biologics and 5 chemical drugs in the pipeline. Among them, 4 biologics at the clinical stages include vascular endothelial growth factor (VEGF) antibody TAB008 at Phase III, and TAD011, TAB014, and TAA013 all at Phase I. TAB008, its leading product candidate, is a bevacizumab biosimilar expected to complete Phase III clinical trials this year and reach the market in 2020 or 2021.

The share price closed today at an underwhelming HKD 6.26 (USD 0.80).


Related news
China-based Tot Biopharmaceutical International Co., Ltd, released price range details for its initial public offering (IPO) to the Stock Exchange of Hong Kong (HKEX).
China-based biotechs Harbour BioMed and Tot Biopharm Co., Ltd, have agreed to work together on the research and development and commercialization of innovative human antibody drugs.
China-based biotechs Tot Biopharm Co., Ltd, and Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) agreed to pair Tot's TAB008, a biosimilar of Roche’s anti-VEGF monoclonal antibody (mAb) bevacizumab (Avastin), in combination with Junshi Bio’s toripalimab (JS001), an innovative recombinant human programmed death-1 (PD-1) monoclonal antibody (mAb).
China-based Tot Biopharm Co., Ltd officially filed to hold an initial public offering (IPO) to the Hong Kong Stock Exchange (HKEX) on April 29.
GBI SOURCE database reveals that a New Drug Application (NDA) has been accepted for review for the programmed death-ligand 1 (PD-L1) antibody atezolizumab, developed by Switzerland-based giant Roche and marketed under the brand name Tecentriq in markets outside China.
  • 1551150346363
  • China
  • Drug
Recent news
Zoé Robledo Aburto, head of Mexico's Social Security Institute (IMSS), last week announced that the public institution will invest MXN 13 billion (USD 676 million) in 2020 as part of a program to complete over 111 new hospitals, 132 family clinics, 120 remodelings, and 200 additional infrastructure projects by the end of 2024.
Luiz Henrique Mandetta, head of Brazil’s Ministry of Health (MoH), last week discussed the Conecte SUS project, which aims to digitalize the Unified Health System (SUS) network, allowing public and private healthcare workers to access patients' clinical records from a centralized database.
GBI analysis shows that Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT) last week approved Monte Verde’s Vilzer (vildagliptin), a first-mover generic of Novartis’ hyperglycemia treatment Galvus/Glucemix/Zomarist​.
The Latin American Association of Pharmaceutical Industries (ALIFAR) shared with The Pharma Letter its plans for the current period of economic challenges and political changes.
  • 1574154772332
  • Argentina,Brazil,Mexico,Colombia,Peru,Venezuela,Chile,Uruguay,Paraguay,Ecuador ,Costa Rica,El Salvador,Bolivia ,Guatemala,Dominican Republic
  • Policy/Regulatory, Company
China-based Maider Medical Industry Equipment Co., Ltd announced that its initial public offering (IPO) will go ahead with the release of 20.9 million shares at RMB 24.79 (USD 3.53) per share on the Shanghai Science and Technology Innovation Board (STAR).
China-based China Grand Pharmaceutical and Healthcare Holdings Ltd (CGP; HK.512) announced it has entered into a licensing agreement with Australia’s Institution for Glycomics at Griffith University, focused on the latter’s first-in-class parainfluenza drug.
The Center for Drug Evaluation (CDE)’s website indicated that a clinical trial filing is currently under review in relation to pan fibroblast growth factor receptor (FGFR) inhibitor erdafitinib (Balversa), filed by Johnson & Johnson's China-based subsidiary Xian Janssen.
Analytics Snapshot

Analytics Snapshot